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ABSTRACT
Oncogenic transformation triggers reprogramming of cell metabolism, as part of 
the tumorigenic process. However, metabolic reprogramming may also increase the 
sensitivity of transformed cells to microenvironmental stress, at the early stages of 
tumor development. Herein, we show that transformation of human breast epithelial 
cells by the p95HER2/611CTF oncogene markedly sensitizes these cells to metabolic 
stress induced by the simultaneous inhibition of glucose and glutamine metabolism. 
In p95HER2/611CTF-transformed cells, metabolic stress activates a TNF related 
apoptosis-inducing ligand (TRAIL)-R and caspase-8-dependent apoptotic process 
that requires prior down-regulation of cellular FLICE-like inhibitor protein (c-FLIP) 
levels. Importantly, sustained mTOR activation is involved in FLIP down-regulation 
and apoptosis induced by metabolic stress. In vivo experiments in immunodeficient 
mice demonstrate a requirement for caspase-8 in restraining primary tumor growth 
of xenografts with p95HER2/611CTF-transformed cells. Collectively, these data define 
a critical role of the extrinsic pathway of apoptosis in the control of tumor initiation 
by microenvironmental cues.
INTRODUCTION
Amplification of a genomic region on chromosome 
17q12 containing the HER2/ERBB2 gene, a member of the 
ERBB receptor family, has been observed in about 25% of 
breast tumors and this is associated with aggressive disease 
and lower survival of patients [1]. Despite the remarkable 
success of anti-HER2/ERBB2 therapies, patients with 
advanced HER2-positive breast cancer frequently display 
primary resistance [2]. Moreover, in patients initially 
sensitive to these agents, acquired resistance may emerge 
over time [2]. A potential mechanism of resistance to 
HER2/ERBB2-directed therapies is the expression of 
an amino terminally truncated form of HER2/ERBB2 
known as p95HER2/611CTF generated by alternative 
initiation of translation [3]. This truncation leads to 
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spontaneous homodimerization which results in a gain-
of-function compared with wild-type HER2/ERBB2 
[3, 4]. p95HER2/611CTF expression leads to deregulation 
of intracellular signalling pathways, such as the 
extracellular signal-regulated kinase (ERK) and the 
phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/
mechanistic target of rapamycin (mTOR) pathways [5] 
that control cell metabolism, growth and proliferation. 
Clinically, patients with high-p95HER2/611CTF tumors 
had significantly worst outcome compared with those with 
low-p95HER2/611CTF tumors [5].
To survive the hostile environment of tumors a 
number of intracellular signalling pathways are activated 
in tumor cells, facilitating tumor growth [6]. Although 
an increased consumption of glucose through aerobic 
glycolysis is important to meet the increased energetic 
and biosynthetic demands of tumor cells [7], glutamine 
is also an essential nutrient to support cell survival and 
growth of many tumor cells [8]. Glutamine contributes 
substantially to maintain macromolecular synthesis, 
glutathione levels and bioenergetics of proliferating 
tumor cells [8]. Importantly, prior to metabolic adaptation, 
oncogenic transformation renders tumor cells initially 
sensitive to nutrient shortage, in particular to glucose and 
glutamine deprivation [9, 10]. However, the molecular 
determinants controlling the cell death response of 
oncogene-transformed cells to nutrient deprivation remain 
to be identified.
The so-called extrinsic pathway of apoptosis 
utilises membrane-localized death receptors of the 
tumor necrosis factor (TNF) receptor superfamily to 
activate the caspases cascade and apoptosis upon ligand 
binding [11]. Activation of TRAIL receptors leads to the 
formation of a death-inducing signaling complex (DISC), 
which includes the receptor itself, the adapter molecule 
FADD and procaspase-8 [12]. Processing and activation 
of caspase-8 at the DISC leads to a cascade of apoptotic 
events which results in the death of the cell. At the DISC 
level, the apoptotic signal may be inhibited by cFLIP, the 
homologue of vFLIP in vertebrate cells [13]. Interestingly, 
in recent years there have been some reports on the 
involvement of TRAIL receptors in cell fate decisions 
after endoplasmic reticulum stress [14, 15]. In addition, 
the induction of an integrated stress response by certain 
antitumor drugs triggers cell death in different tumor cells 
through the activation of TRAIL-R2/DR5-dependent 
apoptosis [16]. 
Here, we examined the impact of inhibiting both 
glycolysis and glutamine metabolism on the viability 
of human breast epithelial cells transformed by the 
p95HER2/611CTF oncogene. We found that metabolic 
stress induces TRAIL-R2/DR5 clustering at the plasma 
membrane and down-regulates FLIP expression, which 
leads to activation of a TRAIL-R/caspase-8-dependent 
apoptotic program in p95HER2/611CTF-transformed 
cells. Remarkably, when glycolysis is inhibited addiction 
of p95HER2/611CTF-transformed cells to glutamine 
relies on the sustained activation of mTOR complexes. 
In addition, in vivo experiments demonstrate a key role 
of caspase-8 in the prevention of p95HER2/611CTF-
mediated tumor formation. Collectively, these results point 
to a role of the extrinsic apoptotic pathway in the control 
of tumor growth by microenvironmental factors.
RESULTS
Expression of p95HER2/611CTF oncogene 
sensitizes human breast epithelial cells to metabolic 
stress-induced cell death through a TRAIL-R and 
caspase-8-dependent apoptotic pathway
MCF10A cells, a non-transformed human mammary 
epithelial cell line, have been used as a model system to 
investigate the biological properties of oncogenes in tumor 
initiation and progression [17–19]. We have examined 
the impact of p95HER2/611CTF expression on the 
cellular response of MCF10A cells to metabolic stress. 
Inhibition of glucose metabolism with 2-deoxyglucose 
(2DG) concurrently with deprivation of glutamine 
markedly induced apoptosis in p95HER2/611CTF cells 
as compared to control cells or cells expressing wild-
type HER2/ERBB2 (wt-HER2) (Figure 1A–1B). These 
observations were extended to the 184A1 cell line, 
another immortalized, non-tumorigenic human breast 
epithelial cell line. We generated a bulk population of 
184A1 cells transformed by retroviral infection with an 
empty vector (mock) or the p95HER2/611CTF-encoding 
vector. Initial studies with these cell lines demonstrated a 
lack of sensitivity of p95HER2-184A1 cells to starvation 
(Supplementary Figure 1A). Western blot analysis in 
the bulk population of p95HER2-184A1 cells revealed 
a markedly reduced HER2 expression as compared to 
p95HER2-MCF10A cells that may be relevant in the 
lack of sensitivity to starvation-induced apoptosis. To 
circumvent this problem we selected different clones from 
the bulk populations of mock and p95HER2 cells which 
were subsequently used to determine HER2 expression 
and their apoptotic response to starvation. Results shown 
in Supplementary Figure 1B demonstrate that whereas 
mock clones were resistant to starvation, metabolic 
stress activated an apoptotic process in the p95HER2 
clones. In both cellular models, apoptosis was inhibited 
in the presence of the HER2/ERBB2 tyrosine kinase 
inhibitor lapatinib (Figure 1C, Supplementary Figure 1C), 
strongly supporting the hypothesis that sensitivity to 
metabolic stress results from the constitutive activation of 
p95HER2/611CTF tyrosine kinase. 
Induction of the extrinsic apoptotic pathway by 
TRAIL receptor activation has been observed in cells 
undergoing endoplasmic reticulum (ER) stress [14, 15]. 
We next studied the role of the TRAIL system in the 
differential activation of apoptosis by the combination 
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of 2DG and glutamine deprivation in p95HER2/611CTF 
cells. Compared to mock cells, p95HER2/611CTF-
transformed cells expressed higher TRAIL-R2/DR5 levels 
at the cell surface (Supplementary Figure 2A, left panel) 
and consequently showed an increased sensitivity to 
exogenous TRAIL (Supplementary Figure 2A. right panel). 
Remarkably, metabolic stress induced caspase-8 activation 
specifically in p95HER2/611CTF cells (Figure 2A), 
suggesting that differential activation of the extrinsic 
apoptotic pathway may underlie the increased sensitivity 
of these cells to metabolic stress. 
Up-regulation of TRAIL-R2/DR5 expression 
following ER stress has been associated to activation of 
apoptosis in various cell types [14, 15]. However, we did 
not observe an increase in either total (Supplementary 
Figure 2B) or surface (Supplementary Figure 2C) 
TRAIL-R2/DR5 levels following metabolic stress 
in p95HER2/611CTF-transformed cells. In contrast, 
treatment with thapsigargin, a potent inducer of ER 
stress, significantly enhanced plasma membrane levels of 
TRAIL-R2/DR5 (Supplementary Figure 2C). Likewise, 
expression levels of FADD and caspase-8, two key 
components of the death-inducing signaling complex 
(DISC) in the extrinsic apoptotic pathway, remained 
unaffected after metabolic stress (Supplementary 
Figure 2B). However, silencing caspase-8 expression 
by RNA interference markedly inhibited metabolic 
stress-induced apoptosis in p95HER2/611CTF cells 
(Figure 2B, Supplementary Figure 3A). Furthermore, 
simultaneous knockdown of both TRAIL-R1/DR4 and 
TRAIL-R2/DR5 significantly reduced apoptosis upon 
metabolic stress (Figure 2B, Supplementary Figure 3B), 
suggesting a role of the TRAIL system in this cell death 
process. Importantly, silencing TRAIL expression by 
siRNA did not prevent apoptosis induced by 2DG in 
glutamine deprived-cells (Figure 2C) indicating that a 
Figure 1: Increased sensitivity of p95HER2/611CTF-overexpressing cells to metabolic stress. (A) Cells were cultured for 
30 h in medium containing the indicated additions and apoptosis was determined as described in Materials and Methods. Western blotting 
shows the expression of p-HER2 (Tyr1248) and total HER2. (B) Apoptosis in mock and p95HER2/611CTF cells incubated for 30 h either 
in complete or Stv medium (glutamine-free medium + 10 mM 2DG) in the presence or absence of Q-VD (20 µM). (C) p95HER2/611CTF 
cells were incubated in control or Stv medium either in the presence or absence of Lapatinib (5 µM), for 30 h to measure apoptosis (left 
panel) or for 16 h to analyze p-HER2 expression (right panel). Error bars, standard deviation (SD) from three independent experiments. 
***P < 0.001, **P < 0.01, *P < 0.05.
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ligand-independent mechanism of apoptosis through the 
extrinsic pathway was activated during metabolic stress, 
specifically in p95HER2/611CTF cells. 
Caspase-8 knockdown promotes tumor growth 
in a xenograft model of p95HER2/611CTF-
expressing cells
Nutrient deprivation is a common feature of rapidly 
growing tumors [20]. To translate our in vitro findings into 
an in vivo model of primary tumor growth we first knocked-
down stably caspase-8 expression in p95HER2/611CTF-
overexpressing breast epithelial cells with shRNA by 
lentiviral infection and determined the apoptotic response 
of these cells to metabolic stress. As shown in Figure 3A, 
stable silencing of caspase-8 expression markedly reduced 
the sensitivity of p95HER2/611CTF cells to metabolic 
stress, further confirming the results obtained with siRNA 
oligonucleotides (Figure  2B and Supplementary Figure 3A). 
It has been shown that HER2/ERBB2 activation 
in MCF10A cells initiates a sequence of events that is 
characteristic of neoplastic progression in early-stage 
epithelial tumours [18]. In addition, expression of the 
p95HER2/611CTF oncogene promotes the development 
of aggressive and invasive mammary tumors in transgenic 
animals [5]. In this regard, p95HER2/611CTF-expressing 
MCF10A cells shows anchorage-independent growth in 
soft agar assays (Supplementary Figure 4A) and invasive 
growth in Matrigel (Supplementary Figure 4B), two 
hallmarks of cell transformation. To examine the role of 
the extrinsic apoptotic pathway in the tumoral behavior 
of p95HER2/611CTF-transformed cells in an in vivo 
setting we then injected control (Scr) or caspase-8-
silenced p95HER2/611CTF cells subcutaneously into 
SCID-beige mice. In agreement with the data about the 
anchorage-independent growth of p95HER2/611CTF 
cells, control cells gave rise to detectable tumors 
within 6 weeks of injection (Figure 3B). Strikingly, we 
observed that caspase-8 knockdown clearly increased 
p95HER2/611CTF-mediated tumorigenicity. Thus, mice 
injected with caspase-8-silenced p95HER2/611CTF cells 
developed tumors with an increased volume (Figure 3B) 
Figure 2: Role of the extrinsic pathway of apoptosis in metabolic stress-induced cell death. (A) Mock or p95HER2/611CTF 
cells were cultured in starvation medium for the indicated times. Following these treatments, caspase-8 activation was assessed by western 
blotting. Results are representative of three independent experiments. (B) p95HER2/611CTF cells were transfected for 48 h either with a 
scrambled oligonucleotide (Scr) or with the indicated siRNAs targeting TRAIL-R1, TRAIL-R2, or Caspase-8. Cells were then cultured 
either in complete or Stv medium, or treated with soluble TRAIL (50 ng/mL) for 30 h and apoptosis was determined (left panel). Error 
bars, SD from three independent experiments. **P < 0.01, *P < 0.05. Protein knockdown was assesed by western blotting (right panel). 
(C) p95HER2/611CTF cells transfected with either a siRNA targeting TRAIL or a scrambled oligonucleotide were incubated for 30 h 
in complete or starvation medium and apoptosis was determined (left panel). Results show the average and range of two independent 
experiments. TRAIL knockdown was assessed by RT-qPCR (right panel) as described in Materials and Methods. 
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and weight (Figure 3C) compared with the control 
group. These results were in line with our in vitro data 
on the key role of the extrinsic apoptotic pathway in 
the hypersensitivity of p95HER2/611CTF-transformed 
cells to metabolic stress. Our data suggest that prior 
to metabolic adaptation and tumor vessels formation, 
primary tumor development will be markedly dependent 
on nutrient availability in the tumor microenvironment 
which in turn controls the activity of the TRAIL-R/
caspase-8 system. Indeed, nuclei staining with 
Hoechst demonstrated the presence of fragmented 
nuclei in sections from control p95HER2/611CTF-
shScr tumors that were markedly reduced in 
p95HER2/611CTF-shCasp8 tumors (Figure 3D). 
These results suggested that caspase-8 knockdown is 
instrumental to bypass cell death in line with the in vitro 
experiments. In addition, analysis of CD31 staining in 
tumor sections showed a significant increase in vessels 
formation in shCasp8 tumors as compared to shScr tumors 
(Figure 3D). Therefore, increased tumor growth in mice 
injected with p95HER2/611CTF-shCasp8 cells is likely 
inducing angiogenesis, thus overcoming their demand for 
oxygen and nutrient supply. 
p95HER2/611CTF expression promotes 
TRAIL-R2/DR5 clustering at the plasma 
membrane upon metabolic stress
To cope with environmental or intrinsic stresses, 
mammalian cells induce an adaptive response through 
the activation of a family of eIF2α protein kinases [21]. 
Upon eIF2α phosphorylation global protein translation is 
inhibited to prevent aggravation of stress. To get further 
insight into the mechanism of metabolic stress-induced 
Figure 3: Caspase-8-dependent inhibition of tumor growth. (A) p95HER2/611CTF cells stably expressing a Scrambled or a 
Caspase 8-targeting shRNA were cultured either in complete or starvation medium and apoptosis was measured (left panel). Caspase-8 
knockdown was determined by western blotting (right panel). Error bars, SD from three independent experiments. ***P < 0.001. 
(B) Subcutaneous growth of p95HER2/611CTF cells stably expressing a Scrambled or a Caspase 8-targeting shRNA injected in SCID-bBeige 
mice. Representative pictures were taken at day 30 after injection. (C) End-stage tumor weight in mice injected with p95HER2/611CTF 
cells stably expressing either a Scrambled oligonucleotide or a Caspase-8-targeting shRNA (n = 8). Graphs shown mean ± SEM. *P < 0.05. 
(D) Representative images and quantification of CD31+ tumor vessel area in mice injected either with p95HER2shScr or p95HER2shCasp8 
cells (n = 8). The vessel area was calculated by the percentage of CD31 area per field.
Oncotarget93693www.impactjournals.com/oncotarget
apoptosis in p95HER2/611CTF cells we investigated the 
role of the eIF2α kinases activated following ER stress 
or aminoacid deprivation, PERK and GCN2, respectively. 
Remarkably, we did not observe differences between 
mock and p95HER2/611CTF cells in the activation of 
eIF2α kinases upon metabolic stress, as determined by 
the phosphorylation of the eukaryotic initiation factor 2 α 
(eIF2α) (Supplementary Figure 5A). Furthermore, PERK 
silencing did not result in the inhibition of apoptosis 
following metabolic stress in p95HER2/611CTF cells 
(Supplementary Figure 5B). In contrast, PERK knockdown 
markedly reduced CAAT/enhancer binding protein 
homologous protein (CHOP) up-regulation and apoptosis 
induced by thapsigargin (Supplementary Figure 5B), 
a widely used activator of ER stress [22]. To further 
analyze the role of ER stress in the apoptotic response of 
p95HER2/611CTF cells to metabolic stress we silenced 
the expression of the other two UPR sensors of ER stress, 
Ire1α and activating transcription factor-6 (ATF6), before 
incubating the cells in glutamine-free medium with 2DG. 
As shown in Supplementary Figure 5C, silencing of either 
Ire1α or ATF6 did not inhibit metabolic stress-induced 
apoptosis in p95HER2/611CTF cells, further excluding a 
role of the UPR in this cell death process.
The general control nonderepressible 2 (GCN2) 
signalling pathway is a major regulatory mechanisms for 
amino acid sensing that can play an adaptive role to sustain 
cell viability in response to glutamine deprivation [23]. 
However, GCN2 has been also involved in the apoptotic 
response of tumor cells to glutamine deprivation [24]. To 
investigate the role of the GCN2 pathway in metabolic 
stress-induced apoptosis in p95HER2/611CTF cells, 
GCN2 expression was silenced by siRNA interference 
prior to incubating the cells in starvation medium. 
Despite inhibiting CHOP induction upon glutamine 
deprivation, GCN2 knockdown failed to provide 
protection against starvation (Supplementary Figure 5D) 
thus excluding a proapoptotic role of the GCN2 pathway 
in p95HER2/611CTF cells subject to metabolic stress.
Ligand-independent assembly of the DISC has 
been demonstrated in the TNF family of death receptors, 
most likely due to the homotypic association of receptors 
mediated by the pre-ligand-binding assembly domain 
(PLAD) [25]. Moreover, the DISC components may co-
localize in an intracellular membrane fraction in breast 
epithelial cells in the absence of TRAIL [26]. Furthermore, 
it was recently shown that ER stress activates a ligand-
independent TRAIL-R2/DR5 multimerization in the 
Golgi apparatus leading to activation of the extrinsic 
apoptotic pathway [15]. Therefore, we investigated if 
metabolic stress-induced apoptosis in p95HER2/611CTF 
cells involved intracellular TRAIL-R2/DR5 clustering. 
We first examined co-localization of TRAIL-R2/DR5 
with Golgi marker GM130 in starved cells or in cells 
treated with ER stress inducer thapsigargin. As shown in 
Figure 4A, TRAIL-R2/DR5 co-localized with GM130 
in p95HER2/611CTF cells treated with thapsigargin, as 
previously demonstrated in other cell lines [15]. However, 
in contrast to the ER stress inducer, metabolic stress did 
not induce co-localization of TRAIL-R2/DR5 with the 
Golgi marker in p95HER2/611CTF cells (Figure 4A). 
Generation of SDS-stable aggregates of TRAIL-R2/
DR5 is a requirement in the activation of caspase-8 and 
apoptosis following TRAIL binding to this receptor [27]. 
To further investigate the role of TRAIL-R2/DR5 in the 
mechanism underlying ligand-independent apoptosis 
upon metabolic stress in p95HER2/611CTF cells we first 
determined by gel electrophoresis formation of SDS-
insoluble aggregates at different times following metabolic 
stress. As shown in Figure 4B, SDS-stable aggregates were 
readily detected upon treatment of p95HER2/611CTF 
cells with 2DG in glutamine-free medium. Clustering of 
TRAIL receptors by TRAIL into high-molecular-weight 
complexes leads to DISC formation where caspase-8 
processing and activation takes place [27]. To determine 
whether metabolic stress induced ligand-independent 
DISC assembly at the cell surface, control or starved cells 
were incubated with biotin-labelled TRAIL (bio-TRAIL) 
at 4°C to facilitate loading of TRAIL receptors with bio-
TRAIL. At low temperature bio-TRAIL does not induce 
DISC assembly but it should allow the isolation of pre-
formed DISC at the cell surface. Remarkably, results 
shown in Figure 4C demonstrate that metabolic stress 
induced DISC formation in p95HER2/611CTF cells but 
not in mock cells. If the different DISC formation between 
p95HER2/611CTF and mock cells is the result of the 
higher expression levels of TRAIL-R2/DR5 at the cell 
surface in p95HER2/611CTF cells is an issue that requires 
further investigation. 
FLIP is a master regulator of metabolic stress-
induced apoptosis in p95HER2/611CTF-
transformed cells
When examining DISC assembly we observed 
an important loss of FLIP proteins specifically in cell 
lysates from p95HER2/611CTF cells upon metabolic 
stress (Figure 4C, lower panel). These results prompted 
us to investigate the role of FLIP in the enhanced 
sensitivity of p95HER2/611CTF cells to metabolic 
stress. Time course analysis of FLIP protein expression 
in both mock and p95HER2/611CTF cells incubated in 
glutamine-free medium with 2DG showed a marked 
down-regulation of both FLIP(L) and FLIP(S) levels 
in p95HER2/611CTF cells when compared with mock 
cells (Figure 5A). Proteasome-mediated  degradation 
was involved in the loss of FLIP proteins in starved 
p95HER2/611CTF cells as it was prevented in the 
presence of the proteasome inhibitor MG132 (Figure 5B, 
left panel) but not by a lysosomal inhibitor (Figure  5B, 
right panel). Importantly, over-expression of FLIP(L) 
protein in p95HER2/611CTF cells significantly 
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reduced apoptosis when these cells where incubated 
in glutamine-free medium with 2DG (Figure 5C), 
which supported a central role of FLIP in modulating 
the response to metabolic stress. Conversely, silencing 
FLIP(L) expression in mock MCF10A cells markedly 
sensitized these cells to metabolic stress (Figure 5D), 
further indicating that maintenance of cellular FLIP(L) 
levels plays a protective role in the apoptotic response to 
metabolic stress in human breast epithelial cells.
mTOR activity governs metabolic stress-induced 
down-regulation of FLIP levels and apoptosis in 
p95HER2/611CTF-expressing cells
Because of its ability to form homodimers 
maintained by disulphide bonds, p95HER2/611CTF 
is a constitutively active form of HER2 that activates 
multiple signalling pathways [5]. Amongst these, 
stimulation of the MAPK/Erk and PI3K/Akt pathways 
converges in the activation of the mTORC1 complex 
[28]. Deregulated activation of the mTORC1 complex 
leads to unrestrained protein synthesis and consequently 
to increased sensitivity to ER stress [29]. Likewise, in 
cells with mTOR over-activation, the maintenance of a 
high rate of protein synthesis under glucose deprivation 
leads to ATP depletion and cell death [9]. To determine the 
role of mTORC1 in the differential activation of apoptosis 
between mock and p95HER2/611CTF cells following 
metabolic stress, we first examined mTORC1 activity 
by measuring the phosphorylation state of the mTORC1 
substrates p70S6K and 4E-BP1. Interestingly, whereas 
levels of phosphorylated p70(S6K) and 4E-BP1 were 
Figure 4: Metabolic stress induces TRAIL DISC formation at the plasma membrane in p95HER2/611CTF cells. 
(A) Confocal microscopy analysis of TRAIL-R2 distribution in p95HER2/611CTF cells either incubated in complete or starvation medium 
or treated with 100 nM Thapsigargin for 21 h, in the presence of Z-VAD (20 µM). Merged images show labelling for DAPI, TRAIL-R2 and 
the Golgi Marker GM130. (B) p95HER2/611CTF cells were incubated either in complete or starvation medium for the indicated times, or 
treated with 100 nM Thapsigargin for 16 h before collecting samples to determine TRAIL-R2 levels. (C) Mock or p95HER2/611CTF cells 
were cultured either in complete or starvation medium, in the presence of Q-VD (20 µM) for 24 h prior to incubation on ice with bio-TRAIL 
(1 µg/ml) for 60 min. Unstimulated receptor controls (US) represent the addition of bio-TRAIL to an equivalent volume of lysate isolated 
from cells kept on ice without bio-TRAIL. DISC isolation and analysis was performed as described in Materials and Methods (upper panel). 
Lower panel shows western blot analysis of proteins in cell lysates. Data shown are representative of 3 independent experiments.
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markedly reduced in mock cells upon metabolic stress, 
mTORC1 activity remained elevated for up to 16 h in 
p95HER2/611CTF cells (Figure 6A). Similar results were 
obtained when AktSer473 phosphorylation was determined 
to assess mTORC2 activity (Figure 6A). Altogether, 
these results suggest that deregulated activation of both 
mTOR complexes as a result of p95HER2/611CTF 
signalling makes these activities unresponsive to 
metabolic stress. We next examined the role of mTOR 
activation in metabolic stress-induced apoptosis by using 
torin1, a highly potent and selective ATP-competitive 
mTOR inhibitor which fully inhibits mTORC1 and 
mTORC2 complexes [30]. As shown in Figure 6B and 
Supplementary Figure 1D, right panel, torin1 completely 
inhibited mTORC1 activities in p95HER2/611CTF 
cells. Furthermore, torin1 also efficiently inhibited 
mTORC2 activity as indicated by the complete 
inhibition of AktSer473 phosphorylation (Figure 6B, 
right panel and Supplementary Figure 1D). Strikingly, 
we observed a marked inhibition of starvation-induced 
apoptosis by torin1 (Figure 6B and Supplementary Figure 
1D, left panels), suggesting an important role of mTOR 
in this cell death process. Interestingly, results shown 
in Figure 6B  demonstrate that FLIP(L) and FLIP(S) 
down-regulation occurs in a mTOR-dependent manner as 
inhibition of mTOR by torin1 significantly restored FLIP 
levels in p95HER2/611CTF cells. 
The role of mTORC1 and mTORC2 activities in 
the sensitivity of p95HER2/611CTF-transformed cells 
to metabolic stress was further studied in experiments 
silencing Raptor or Rictor expression with a shRNA 
lentiviral vector. As shown in Figure 6C, Raptor 
Figure 5: FLIP levels control cell death induced by metabolic stress. (A) FLIP levels in mock and p95HER2/611CTF cells 
cultured under starvation conditions. (B) FLIP levels in cells were cultured either in complete (NT) or Starvation medium for 16 h, in the 
presence or absence of 10 µM MG132 (left panel) or 400 nM Bafilomycin A (right panel). Results are representative of three independent 
experiments. (C) Apoptosis was assessed in FLIPL–overexpressing p95HER2/611CTF cells cultured in Stv or treated with TRAIL 
(50 ng/mL) for 30 h. Insert shows FLIPL overexpression as measured by western-blotting. (D) Apoptosis in mock cells transfected for 
16 h either with a Scrambled oligonucleotide or siRNAs targeting FLIPL, Caspase-8, or both and then cultured in complete or Stv medium 
for 6 h (upper panel). Protein knockdown was determined 16 h after transfection by western blotting (lower panel). Error bars, SD from 
three independent experiments. ***P < 0.001, **P < 0.01, *P < 0.05.
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knockdown partially reduced the sensitivity of cells to 
glycolysis inhibition in glutamine-deprived medium, 
similarly to what is observed in cultures treated with 
rapamycin. Interestingly, silencing Rictor expression 
markedly inhibited FLIP down-regulation and apoptosis 
upon metabolic stress (Figure 6C), almost like the 
inhibition observed with Torin-1 (Figure 6B and 6C). 
Although both mTOR complexes seem to counteract the 
activation of apoptosis after metabolic stress, our results 
underscore the prominent role of mTORC2 activation as an 
effector of the signalling pathway leading to FLIP down-
regulation and apoptosis activation in p95HER2/611CTF-
transformed cells undergoing metabolic stress.
DISCUSSION
Uncontrolled cell proliferation in tumors results 
in the development of aberrant vasculature in which the 
delivery of nutrients is drastically reduced leading to 
microenvironmental stress. To cope with this extrinsic 
form of stress, tumor cells must activate different adaptive 
responses [6]. However, different observations indicate 
that prior to adaptation oncogene-transformed cells may 
become very sensitive to nutrient deprivation and this 
represent a potential Achilles’heel in tumor progression 
[31–33]. 
Although MCF10A cells express markers not 
observed in mammary gland tissue [34] and show 
genetic abnormalities [35], they recapitulate many 
features of normal breast epithelium when grown in 
three-dimensional (3D) cultures, including the formation 
of growth-arrested polarized acini with a hollow lumen 
and basal deposition of basement membrane components 
[17]. Moreover, MCF10A cells and isogenic progression 
series have recently been used to identify driver genes 
associated with tumor progression from preinvasive to 
invasive cellular phenotypes as seen in primary breast 
cancer [19].  Interestingly, it has been demonstrated that 
Her2 activation in MCF10A cells initiates a sequence 
of events that is characteristic of neoplastic progression 
Figure 6: Role of mTOR complexes in apoptosis induced by metabolic stress. (A) Cells were cultured in Stv medium for 
the indicated times. Following these treatments, mTORC1 and mTORC2 activation (p-p70/S6K, p-4EBP1 and p-AktSer473), was assessed 
by western blotting. Results are representative of 4 independent experiments. (B) Left panel shows apoptosis in p95HER2/611CTF cells 
cultured in complete or stv medium in the presence or absence of Torin-1 (250 nM). FLIP levels and mTORC1/mTORC2 activities were 
determined by western blot analysis (right panels). (C) Apoptosis in p95HER2/611CTF cells stably expressing a Scrambled, Raptor or 
Rictor shRNA cultured either in complete or stv medium (left panel). Where indicated, Rapamycin (5 µM) or Torin (250 nM) were added 
to the medium. Levels of FLIP, Raptor and Rictor proteins upon 16 h of treatment are shown in the right panel. Error bars, SD from three 
independent experiments. ***P < 0.001, **P < 0.01, *P < 0.05. (D) Schematic overview of the differential response to metabolic stress in 
control and p95HER2/611CTF cells.
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in early-stage epithelial tumours [18]. In our work we 
have investigated the response of human breast epithelial 
cells MCF10A transformed by the p95HER2/611CTF 
oncogene to metabolic stress. Our results demonstrate 
that p95HER2/611CTF-transformed cells are strikingly 
sensitive to the simultaneous inhibition of glucose and 
glutamine metabolism compared to untransformed cells 
or cells transformed with wild-type HER2. Differences in 
the activation levels of multiple signalling pathways and 
in the resulting transcriptome between wild-type HER2 
and p95HER2/611CTF-transformed cells [5] may explain 
the strikingly different sensitivity to metabolic stress. 
Interestingly, p95HER2/611CTF expression in breast 
cancers or ectopic expression of p95HER2/611CTF in 
breast epithelial cells is associated to an increased rate of 
proliferation and marked sensitivity to different antitumor 
agents [36]. Likewise, expression of a constitutively 
active form of rat HER2 (NeuT) sensitizes human breast 
epithelial cells to genotoxic stress [37] and to agents that 
induce endoplasmic reticulum (ER) stress [14]. Together, 
these data suggest that constitutively active forms of 
HER2/ERBB2 may sensitize human breast epithelial cells 
to different stress-inducing conditions.
Our results clearly demonstrate a key role of 
caspase-8 and pro-apoptotic TRAIL receptors in apoptosis 
induced upon metabolic stress in p95HER2/611CTF-
transformed cells. Interestingly, TRAIL-R2/DR5 and 
caspase-8 have been shown to participate in the apoptotic 
response induced following ER stress in different cell 
types [14, 15]), through the formation of a TRAIL-
independent death-inducing signalling complex (DISC) 
in the Golgi apparatus [15]. However, our results 
demonstrate that in contrast to ER stress-mediated cell 
death, metabolic stress-induced apoptosis neither involves 
the activation of the unfolded protein response (UPR) 
pathways nor the accumulation of TRAIL-R2/DR5 in the 
Golgi apparatus. Instead, apoptosis induced by metabolic 
stress in p95HER2/611CTF-transformed cells requires 
TRAIL-independent DISC formation at the plasma 
membrane. In this regard, ligand-independent assembly 
of the DISC components has been described in death 
receptors of the TNF family, by the homotypic association 
of receptors through the pre-ligand-binding assembly 
domain (PLAD) [25]. Regarding TRAIL receptors, ectopic 
expression of TRAIL-R2/DR5 is sufficient to induce 
TRAIL-independent apoptosis [38]. Interestingly, our 
data show that p95HER2/611CTF expression increased 
TRAIL-R2/DR5 expression at the cell surface in breast 
epithelial cells. Moreover, TRAIL-R2/DR5 has been 
found to have a strong tendency to self-associate as a 
dimer which can be followed by the weak recruitment of a 
third monomer [39]. Whether or not nutrient starvation is 
stabilizing the trimeric form of TRAIL death receptors in 
p95HER2/611CTF-transformed cells is an important issue 
that warrants further investigation. 
Constitutive activation of the intrinsic tyrosine 
kinase activity of p95HER2/611CTF leads to potent 
stimulation of signalling pathways MAPK/Erk and PI3K/
Akt among others, which are important for its enhanced 
oncogenic potential [5]. Some of the signalling pathways 
activated in p95HER2/611CTF-transformed cells are 
known to converge in mTORC1 activation [40]. Chronic 
activation of mTORC1 results in an increased sensitivity 
to ER stress [14, 29]. However, our data demonstrate that 
UPR signalling is not involved in the enhanced sensitivity 
of p95HER2/611CTF-transformed cells to metabolic 
stress. Likewise, metabolic stress may activate a GCN2/
eIF2α/ATF4-dependent apoptotic pathway in cells with 
an elevated MEK1 activity [41].  Nevertheless, silencing 
GCN2 in p95HER2/611CTF-transformed cells did not 
abrogate metabolic stress-induced cell death. Collectively, 
our data indicate that signalling pathways activated by 
ER stress or amino acid deprivation are dispensable for 
apoptosis induced following metabolic stress in human 
breast epithelial cells transformed with p95HER2/611CTF. 
A critical mechanism involved in regulating 
sensitivity to proapoptotic TRAIL receptor activation 
involves the modulation of cFLIP
L
 and cFLIP
S
 expression 
levels [13]. These are short-lived inhibitory proteins 
[42] that are expressed at high levels in breast cancers 
[43]. In breast cancer cells, selective suppression of 
FLIP expression by RNA interference induces caspase-
8-dependent apoptosis both in vitro and in vivo [44]. 
Collectively, our results reveal for the first time a key 
role of FLIP in the preservation of cell viability under 
metabolic stress in breast epithelial cells. Our data point 
at the deregulation of the mechanisms controlling the 
proteasomal degradation of FLIP [45] as an important 
step in the process leading to glycolysis and glutamine 
addiction in p95HER2/611CTF-transformed cells. A 
major finding of our study is that activity of the mTORC2 
complex, in cooperation with mTORC1, is critically 
involved in the down-regulation of FLIP expression and 
apoptosis in starved p95HER2/611CTF-transformed 
cells. mTORC2 has been shown to increase c-Myc levels 
through the inactivation of class IIa histone deacetylases 
[46] and c-Myc is a transcriptional repressor of FLIP 
gene [47]. However, our results indicate that stability 
of FLIP proteins is most likely the mechanism involved 
in metabolic stress-induced FLIP down-regulation in 
p95HER2/611CTF-transformed cells. Moreover, our 
data not shown indicate the down-regulation of c-Myc 
protein expression following metabolic stress, further 
supporting a c-Myc-independent regulation of FLIP levels 
in p95HER2/611CTF-transformed cells. Unlike mTORC1 
whose activity depends on the availability of amino acids 
[48], it has been recently demonstrated that mTORC2 is 
activated when glutamine levels become limited [49]. 
Furthermore, mTORC2 has been demonstrated previously 
to increase directly the stability of different kinases of the 
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AGC kinase family via phosphorylation at a conserved 
turn motif [50]. On the contrary, phosphorylation by 
mTORC2 of ubiquitin ligase subunit Fbw8 enhances 
its stability allowing ubiquitination and degradation of 
mTORC1-phosphorylated insulin receptor substrate-1 
(IRS-1) [51]. In this regard, further experiments are 
needed to characterize the mechanism by which FLIP 
proteins turnover is controlled in a concerted fashion by 
both mTOR complexes in p95HER2/611CTF-transformed 
cells undergoing nutrient deprivation. 
In summary, we have identified in p95HER2/611CTF-
transformed cells a cell death mechanism activated 
by metabolic stress that may be relevant in the initial 
sensitivity of early stage tumors to the nutrient deprivation 
conditions of the tumor microenvironment (Figure 6D). 
Our data suggest that at early stages of tumor growth, when 
p95HER2/611CTF-transformed cells start proliferating 
within the tumor, nutrient limitation and the likely increase 
in hypoxia would activate TRAIL-R/caspase-8 system and 
cell death. Despite the initial sensitivity of tumor cells to 
the adverse conditions of the tumor microenvironment, 
activation of anti-apoptotic mechanisms and angiogenesis 
would allow tumor progression. In this respect, given 
the complexity of the human tumors, further studies in 
heterotypic in vitro models for tumor-stromal interactions 
are warranted to ascertain the impact of the tumor 
microenvironment in tumor cell fate decisions under 
nutrient limitation. In these models, deciphering the 
adaptive responses of tumor cells that may be involved in 
overcoming the apoptotic mechanism described in our work 
would reveal potential therapeutic targets. 
MATERIALS AND METHODS
Cell culture
MCF10A, 184A1 and MCF10A-derived cell lines 
were maintained in DMEM/F12 medium supplemented 
with 5% donor horse serum (Gibco), 2 mM L-glutamine, 
20 ng/ml of epidermal growth factor (EGF), 10 µg/ml 
of insulin, 100 ng/ml of cholera toxin, 0.5 µg/ml of 
hydrocortisone, 5 µg/ml Transferrin (184A1), 50 U/ml of 
penicillin and 50 µg/ml of streptomycin. MDA-MB231 
and HEK293-T cells were maintained in DMEM medium 
supplemented with 10% fetal bovine serum (Gibco), 
2 mM L-glutamine, 50 U of penicillin/ml and 50 µg of 
streptomycin/ml. All cultures were incubated at 37ºC in a 
5% CO2-humidified, 95% air incubator.
Reagents and antibodies
Media supplements and chemical reagents for 
molecular biology and buffer preparation were from 
Sigma-Aldrich, (St. Louis, MO, USA). Mouse anti-
a-tubulin antibody, thapsigargin, human insulin, 
hydrocortisone, 2-deoxyglucose, DAPI (diamidino-2-
phenylindole) and puromycin were obtained from Sigma-
Aldrich. Anti-FADD, anti-GM130 antibodies and PE-
IgG Isotype control were obtained from BD Biosciences 
(Erembodegem, Belgium). Anti-human PE-TRAIL-R2 
antibody was from Biolegend (San Diego, USA).  Her-
2/ERBB2, pHer2 (Tyr 1248), p4E-BP1, 4E-BP1 and 
caspase-8 antibodies were from Upstate Millipore (NY, 
USA). GAPDH and GCN2 antibodies were from Santa 
Cruz (CA, USA). Anti-TRAIL-R1 and anti-TRAIL-R2 
were from R&D Systems (Minneapolis, USA). Anti-c-
FLIP monoclonal antibodies NF6 and 7F10 were from 
Alexis Corporation (Lausen, Switzerland) and from Enzo 
Life Sciences (NY, USA), respectively. Anti p-AKTSer473, 
anti-AKT, anti-p-eIF2α, anti-eIF2α, anti-Ire1α, anti-
p-P70S6K, anti-P70S6K, anti-PERK, anti-CHOP and 
anti-cleaved caspase-8 antibodies were purchased from 
Cell Signalling Technology (CA, USA). Anti-p4E-
BP1 and anti-4E-BP1 antibodies were from Upstate-
Millipore (NY, USA). Horseradish peroxidase or FITC-
conjugated secondary antibodies were obtained from 
DAKO (Cambridge, UK). Cy3 or Alexa 488-conjugated 
secondary antibodies were from Jackson ImmunoResearch 
(Baltimore Pike, PA, USA). Human EGF was from 
Peprotech (London, UK). Recombinant human TRAIL 
was produced, and byotinilated as previously described 
[52]. Lapatinib and MG132, were purchased from 
Selleck Chemicals (Houston, Texas, USA). Q-VD was 
from AppexBio (Houston, USA). zVAD-fmk was from 
Bachem AG (Bachem, Bubendorf, Switzerland). Torin1 
was purchased from TOCRIS Bioscience (Bristol, UK). 
Bafilomycin A was from LC Laboratories (MA, USA). 
 Determination of apoptosis 
Cells (3 × 105/well) were treated in 6-well plates 
as indicated in the figure legends. After treatment, 
hypodiploid apoptotic cells were detected by flow 
cytometry according to published procedures [53]. 
Apoptotic cells are expressed as percentage of the total 
cells counted.
Immunoblot analysis of proteins 
Cells (3 × 105) were washed with phosphate-buffered 
saline (PBS) and lysed in TR3 buffer (10 mM Na2HPO4, 
10% Glycerol, 3% SDS). Protein content was measured 
with the Bradford reagent (Bio-Rad Laboratories, USA), 
before adding Laemmli sample buffer. Proteins were 
resolved on SDS-polyacrylamide minigels and detected 
as described previously [53]. Tubulin and GAPDH were 
used as protein loading controls. 
Real time-qPCR
mRNA expression was analyzed in triplicate by 
RT-qPCR on the ABI Prism7500 sequence detection 
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system using predesigned Assay-on-demand primers and 
probes (Applied Biosystems). Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT1 Hs01003267_m1) was 
used as an internal control and mRNA expression levels 
of ATF6 and TRAIL were given as fraction of mRNA 
levels in control cells. Primers and probes used were: 
ATF6 (ATF6 Hs 00232586_m1) and TRAIL (TNFSF10 
Hs00921974_m1).
RNA interference
siRNAs against TRAIL-R1, TRAIL-R2, TRAIL, 
Caspase-8, FLIP(L), PERK, GCN2, Ire1α, ATF6, 
and non-targeting scrambled oligonucleotide were 
synthesized by Sigma (St. Louis, MO, USA). Cells 
were transfected with siRNAs using DharmaFECT-1 
(Dharmacon) as described by the manufacturer. After 6 h, 
transfection medium was replaced with regular medium 
and cells were further incubated for 48 h before further 
analysis.
siRNAs
TRAIL-R1#1
TRAIL-R1#2
5′-GGAACUUUCCGGAAUGACAd
TdT-3′
5′-CAGACUCGCUGUCCACUUU
dTdT-3′
TRAIL-R2#1
TRAIL-R2#2
5′-GACCCUUGUGCUCGUUGUCd
TdT-3′
5′-UCAUGUAUCUAGAAGGUAUd
TdT-3′
TRAIL: 5′-GAAUAUGGACUCUAUUCCAd
TdT-3′
Caspase-8#1
Caspase-8#2
Caspase-8#3
5′-GGAGCUGCUCUUCCCAAUUd
TdT-3′
5′- GUUCCUGAGCCUGGACUACd
TdT-3′
5′- AACUACCAGAAAGGUAUACC
UdTdT-3′
FLIP
L
: 5′-CCUAGGAAUCUGCCUGAUAdT
dT-3′
PERK: 5′-CAAACUGUAUAACGGUUUAdT
dT-3′
GCN2: 5′-CAGCAGAAAUCAUGUACGA
UU-3′
IRE1α: 5′-GCGUCUUUUACUACGUAAUdT
dT-3′
ATF6: 5′-GCAACCAAUUAUCAGUUUAdT
dT-3′
Scrambled: 5′-CUUUGGGUGAUCUACGUUAdT
dT-3′
Analysis of TRAIL receptors by flow cytometry 
Cells were detached with trypsin solution and 
resuspended in growth media. After incubation for 
15 minutes under cell culture conditions (37ºC in a 5% 
CO2-humidified, 95% air incubator), cells were washed 
with ice-cold phosphate-buffered saline (PBS) and 
resuspended in PBS. Cells were then labelled either with 
5 µg/ml of anti-TRAIL-R2-PE, antibody or an IgG-PE 
control antibody (BD Bioscience) for 30 minutes on 
ice and darkness. Analysis of the receptor cell surface 
expression was carried out in a FACSCalibur cytometer 
using the Cell Quest Software (Becton Dickinson, 
Mountain View, CA, USA).
DISC isolation
DISC precipitation was performed using biotin-
tagged recombinant TRAIL (bio-TRAIL). Cells were 
cultured either in complete or starvation medium in the 
presence of Q-VD (20 µM) for 24 h.  After this incubation, 
medium was replaced with ice-cold fresh medium, and 
cells incubated on ice with bio-TRAIL for 1 hour to allow 
loading of TRAIL-Rs with TRAIL [54]. Unbound TRAIL 
was then removed by washing the cells three times with 
ice-cold PBS and cells were lysed in 3 ml of lysis buffer 
(30 mM Tris/HCl pH 7.5, 150 mM NaCl, 10% glycerol, 
1% Triton X-100) containing Complete Mini protease 
inhibitor cocktail tablets (Roche Molecular Biochemicals) 
for 30 min on ice followed by centrifugation at 15,000 × g 
for 30 min at 4ºC. To provide an unstimulated receptor 
control, bio-TRAIL was added to lysates from untreated 
cells. DISC was then precipitated from lysates containing 
the same amount of protein, using 30 µl of streptavidin-
agarose beads at 4ºC overnight. Precipitates were washed 
six times in lysis buffer, and receptor complexes were 
eluted with 30 µl of sample buffer. Western blotting was 
performed as described above.
Lentiviral and retroviral vectors
HER2, p95HER2/611CTF and FLIP(L) retroviral 
vectors for stable gene expression have been described 
previously [26, 36]. For silencing experiments, shRNAs 
against caspase-8, Raptor and Rictor in a pSUPER vector 
(OligoEngine) were digested and cloned between EcoR1 
and Cla1 into a H1 promoter-driven GFP-encoding 
pLVTHM lentiviral vector [55]. Lentiviruses and 
retroviruses were produced by transfection of HEK293-T 
cells by the calcium phosphate method with the 
corresponding vectors. Lentivirus or retrovirus-containing 
supernatants were collected 48 h after transfection and 
concentrated by ultracentrifugation at 22,000 rpm for 
90 minutes at 4ºC.
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Generation of MCF10A cell lines
Stable populations of MCF10A and 184A1 cells 
infected with retroviruses were obtained after selection 
in culture medium containing puromycin (1.5 µg/ml) 
during 48 h. MCF10A cells infected with GFP-expressing 
lentiviruses were detected by flow cytometry.  
Confocal microscopy analysis 
Cells were grown on coverslips and fixed in 
4% paraformaldehyde for 10 minutes at RT and 
permeabilized with 0.5% Triton X-100. Then cells 
were incubated with primary antibodies for 1 hour at 
room temperature, washed with 0.1%PBS-Tween, and 
incubated with the appropriate fluorescent secondary 
antibody for 1 hour. Nuclei were stained with DAPI 
(1 μg/ml) after secondary labelling. Confocal images 
were captured using TCS SP5 confocal Leica laser 
scanning systems equipped with DMI60000 microscope. 
Image processing was carried out using the Leica (LAS) 
and Adobe Photoshop software. For presentation, whole 
images were adjusted for intensity level, contrast, and/
or brightness. 
Soft-agar colony formation assay
To measure anchorage-independent growth, cells 
were detached with trypsin and resuspended in growth 
medium. Plates were prepared with a coating of 0,75% 
low melting agarose in growth medium and then overlaid 
with a suspension of cells in 0,45% low-melting agarose 
(2.5 × 104 cells/well). Plates were maintained for 26 days 
at 37ºC in a 5% CO2-humidified, 95% air incubator and 
the cells were fed with 200 µl of growth media every 
3 days. Colonies were stained with crystal violet at 0.01% 
in H20 with 10% EtOH, for 30 minutes.
Acini formation in matrigel
Morphogenesis assay were performed as previously 
described [56]. Briefly, mock, p95HER2/611CTF and 
MDA-MB231 cells were resuspended in assay medium 
(DMEM/F12 supplemented with 2% donor horse serum, 
10 μg of insulin/ml, 100 ng of cholera toxin/ml, 0.5 μg 
of hydrocortisone/ml, and 5 ng of EGF/ml). Eight-well 
RS glass slides (BD Falcon) were coated with 40 μl of 
Matrigel per well. Then, 5 × 103 cells were plated per well 
in assay medium containing a final concentration of 2% 
Matrigel. Assay medium containing 2% Matrigel was 
replaced every 4 days.
Animals 
SCID-bBeige (C.B-Igh-1b/GbmsTac-Prkdcscid-
LystbgN7) mice were purchased from Taconic. Housing 
and all experimental animal procedures were approved 
by the Institutional Animal Care and Research Advisory 
Committee of the K.U.Leuven (Belgium).
Tumor model
10 × 106 cells MCF10A-p95shSCR or MCF10A-
p95shCASP8 adherent growing human cells were injected 
subcutaneously at the right side of the mouse in a volume 
of 100 µl of Matrigel diluted (1:1) in PBS. Tumor volumes 
were measured three times a week with a caliper and 
calculated using the formula: V =  π × (d2 × D)/6, where d 
is the minor tumor axis and D is the major tumor axis. At 
the end stage, tumor weight was registered.
Histology and immunostainings 
For serial sections cut at 7 μm thickness, tumor 
samples were fixed in 2% PFA overnight at 4°C, 
dehydrated and embedded in paraffin. Paraffin slides were 
first rehydrated to further proceed with antigen retrieval in 
citrate solution (DAKO). The sections were blocked with 
the appropriate serum (DAKO) and incubated overnight 
with rat anti-CD31 (BD Pharmingen) 1:200. Appropiate 
secondary antibodies were added with Hoescht 33342 
(Life thechnologies). ProLong Gold mounting medium 
was used. Microscopic analysis was done with an Olympus 
BX41 microscope and CellSense imaging software.
Statistical analysis 
All data are presented as the mean ± SE of at least 
three independent experiments. The differences among 
different groups were determined by the Student’s 
t test. P < 0.05 was considered significant. ***P < 0.001; 
**P < 0.01; *P < 0.05. 
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